Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2018 | EBMT 2018: Updates on advanced Hodgkin lymphoma treatment

Martin Hutchings • 19 Mar 2018
EBMT 2018
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Nivolumab Pembrolizumab

Treatment of advanced Hodgkin lymphoma has evolved dramatically in the last 10 years, especially with the introduction of PET-response adapted treatment and the introduction of novel agents. Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark discusses the latest advances and how they have changed the way we treat advanced Hodgkin lymphoma. This video was recorded at the EBMT 2018 Annual Meeting, held in Lisbon, Portugal.

More from Martin Hutchings

The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
18:55
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
Elizabeth Budde et al. • 28 Sep 2025
Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
1:49
Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
Martin Hutchings • 7 Dec 2024
The BP41072 trial: glofitamab plus englumafusp alfa in patients with R/R B-NHL
3:17
The BP41072 trial: glofitamab plus englumafusp alfa in patients with R/R B-NHL
Martin Hutchings • 7 Dec 2024
Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL
2:02
Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL
Martin Hutchings • 7 Dec 2024

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals